A Phase 1 interventional study of Valaciclovir in Herpes Simplex, sponsored by GlaxoSmithKline. Completed at 13 sites in 3 countries. Open to participants aged 1 Month to 6 Years. Per ClinicalTrials.gov, last updated 2017-09-11.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing valacyclovir in Herpes Simplex — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Simplex.
Among the 24 studies testing valacyclovir in Herpes Simplex, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2003, is one of 6 in phase 1, and was the 11th registered.
166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.
Browse Herpes Simplex studies →None of the 24 studies testing valacyclovir in Herpes Simplex is open now. The open studies under Herpes Simplex, anywhere →
Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →
Of the 10 Herpes Simplex studies recruiting now, 4 (40%) set no upper age limit and 1 (10%) stops at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 1 Month to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 3 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 66 across 113 interventional studies indexed under Herpes Simplex.
Median enrollment 33 across the 21 interventional studies. Of the 21 that completed or were terminated, 7 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 24 have an industry lead sponsor. The 9 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
20 studies in Herpes Simplex by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 19 finished, 6 (32%) have results posted.
Among the 20 studies in Herpes Simplex by GlaxoSmithKline, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2003, is one of 4 in phase 1, and was the 10th registered.
GlaxoSmithKline’s Herpes Simplex studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing valacyclovir in Herpes Simplex, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 20 in Herpes Simplex:
This tab as a report to print or save as PDF → With an account.
Limited data are available on valaciclovir use in children and valaciclovir is not currently approved for use in pediatrics. The marketed formulation of valaciclovir is not ideal for use in pre-adolescent patients who may have trouble swallowing solid oral dosage forms. An extemporaneous suspension formulation of valaciclovir has been developed to expedite the provision of benefits to children similar to those from administration of valaciclovir solid formulations in adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the age group of 2 to less than 6 years will be included
Drug: Valaciclovir
Subjects in the age group of 1 to less than 2 years will be included
Drug: Valaciclovir
Subjects in the age group of 6 months to less than 1 year will be included
Drug: Valaciclovir
Subjects in the age group of 3 months to less than 6 months will be included
Drug: Valaciclovir
Subjects in the age group of 1 month to less than 3 months will be included
Drug: Valaciclovir
Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
Plasma acyclovir and valaciclovir concentrations pre-dose (within 15 minutes of dose administration) and at 0.5, 1, 2, 4 and 6 hours following administration of the valaciclovir oral suspension dose.
Time frame: 0.5, 1, 2, 4 and 6 hours
Safety monitoring throughout the study and at the follow up evaluation 2-4 days after the single dose of study medication.
Time frame: Up to Day 5
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Jan 2003 to primary completion in Feb 2007, 49 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valacyclovir